Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs

Case Report

Published on 13 Dec 2024

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review

in Pharmacology of Anti-Cancer Drugs

Huang Chen
Menglan Zhang
Liyan Bai
Yun Niu
Xiaowei Wang
Ruiying Jiang
Ye Wang
Qianqian Feng
Bei Wang
Tingli Dai

Frontiers in Oncology

doi 10.3389/fonc.2024.1453259

1,291 views
1 citation

Review

Published on 11 Dec 2024

The antitumor mechanisms of glabridin and drug delivery strategies for enhancing its bioavailability

in Pharmacology of Anti-Cancer Drugs

Chong Li
Yu Wang
Wenjing Zhang
Xiaoman Yang
Yufang Wang
Guanqun Hou
Dongli Wang
Bingbing Han
Yimin Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1506588

2,117 views
1 citation

Correction

Published on 06 Dec 2024

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

in Pharmacology of Anti-Cancer Drugs

Graziana Digiacomo
Claudia Fumarola
Silvia La Monica
Mara Bonelli
Andrea Cavazzoni
Maricla Galetti
Rita Terenziani
Kamal Eltayeb
Francesco Volta
Silvia Zoppi

Frontiers in Oncology

doi 10.3389/fonc.2024.1532291

659 views

Editorial

Published on 06 Dec 2024

Editorial: Photodynamic therapy: challenges and innovations for treating cancer

in Pharmacology of Anti-Cancer Drugs

Newton Soares da Silva
Juliana Ferreira-Strixino
Cristina Pacheco-Soares

Frontiers in Oncology

doi 10.3389/fonc.2024.1526550

639 views

Original Research

Published on 05 Dec 2024

Pembrolizumab versus sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis

in Pharmacology of Anti-Cancer Drugs

Zhengzheng Xia
Juan Hong
Xiangyang Yu
Yuhua Ran
Huali Xie
Ziyuan Zhou
Jing Zuo
Tujia Chen
Jun Meng
Jun Yang

Frontiers in Oncology

doi 10.3389/fonc.2024.1422039

1,245 views
1 citation

Original Research

Published on 05 Dec 2024

Cutaneous adverse events due to checkpoint inhibitors – a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022

in Pharmacology of Anti-Cancer Drugs

Clara Furrer-Matcau
Chloé Sieber
Dirk Lehnick
Christoph Urs Brand
Balthasar Hug

Frontiers in Oncology

doi 10.3389/fonc.2024.1485594

1,302 views

Correction

Published on 03 Dec 2024

Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β-catenin activating FOXO3a signaling

in Pharmacology of Anti-Cancer Drugs

Jiahui Wu
Xiao He
Ziwei Xiong
Lingyu Shi
Daofeng Chen
Yulin Feng
Quan Wen

Frontiers in Oncology

doi 10.3389/fonc.2024.1515205

706 views

Editorial

Published on 02 Dec 2024

Editorial: DNA methylation in cancer therapy: therapeutic targets and molecular mechanism

in Pharmacology of Anti-Cancer Drugs

Guoyi Yan
Shaofeng Duan
Jinyang Cai

Frontiers in Oncology

doi 10.3389/fonc.2024.1508214

744 views

Correction

Published on 27 Nov 2024

Corrigendum: Chamaejasmin B decreases malignant characteristics of mouse melanoma B16F0 and B16F10 cells

in Pharmacology of Anti-Cancer Drugs

Lingling Si
Xinyan Yan
Yan Wang
Boxue Ren
Huanhuan Ren
Yangfang Ding
Qiusheng Zheng
Defang Li
Ying Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1472829

573 views

Correction

Published on 25 Nov 2024

Corrigendum: Long non-coding RNA SNHG1 regulates the Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways via EZH2 to affect the proliferation, apoptosis, and autophagy of prostate cancer cell

in Pharmacology of Anti-Cancer Drugs

Junyi Chen
Fubo Wang
Huan Xu
Lingfan Xu
Dong Chen
Jialiang Wang
Sihuai Huang
Yiqun Wen
Longmin Fang

Frontiers in Oncology

doi 10.3389/fonc.2024.1501882

1,214 views

Review

Published on 25 Nov 2024

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

in Pharmacology of Anti-Cancer Drugs

Zhe Zhu
Wenjing Xuan
Chaohui Wang
Chancan Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1481777

1,855 views

Case Report

Published on 20 Nov 2024

Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion–positive glioblastoma

in Pharmacology of Anti-Cancer Drugs

Luigia Turco
Rosa Della Monica
Pasqualina Giordano
Mariella Cuomo
Manuele Biazzo
Baptiste Mateu
Raimondo Di Liello
Bruno Daniele
Nicola Normanno
Antonella De Luca

Frontiers in Oncology

doi 10.3389/fonc.2024.1458990

1,615 views
1 citation

Review

Published on 12 Nov 2024

Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects

in Pharmacology of Anti-Cancer Drugs

Parminder Kaur
Pankaj Sharma
Prateek Bhatia
Minu Singh

Frontiers in Oncology

doi 10.3389/fonc.2024.1445794

1,472 views

Original Research

Published on 08 Nov 2024

Mechanism of luteolin against non-small-cell lung cancer: a study based on network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experiments

in Pharmacology of Anti-Cancer Drugs

Jihang Zhang
Changling Li
Wenyi Li
Zhenpeng Shi
Zhenguo Liu
Junyu Zhou
Jing Tang
Zixuan Ren
Yun Qiao
Deshan Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1471109

2,820 views
1 citation

Correction

Published on 28 Oct 2024

Corrigendum: Dietary polyphenols, resveratrol and pterostilbene exhibit antitumor activity on an HPV E6-positive cervical cancer model: an in vitro and in vivo analysis

in Pharmacology of Anti-Cancer Drugs

Kaushiki Chatterjee
Sumit Mukherjee
Jonathan Vanmanen
Probal Banerjee
Jimmie E. Fata

Frontiers in Oncology

doi 10.3389/fonc.2024.1483410

717 views

Review

Published on 23 Oct 2024

Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?

in Pharmacology of Anti-Cancer Drugs

Shadiya Fawzul Ameer
Muna Yusuf Mohamed
Qubaa Ahmed Elzubair
Elham Abdullatif M. Sharif
Wisam Nabeel Ibrahim

Frontiers in Oncology

doi 10.3389/fonc.2024.1438040

5,102 views
6 citations